To evaluate the efficacy and safety of recombinant humanized collagen (type III) solution for injection combined with SkinCeuticals recombinant humanized collagen (RHC) serum Participants will be assessed by subjective questionnaire (FACE-Q Satisfaction with skin,Global Aesthetic Improvement Scale, et al) and some medical instruments (VISIA,Ultrascan UC22 et al)

With the growth of photoaging and age, more people have the appearance of fine lines, skin laxity, roughness. Clinical evidences shown that RHC III injection can effectively improve fine line, skin plumpness and firmness to some extent; SkinCeutials RHC serum is capable of improving skin plumpness, firmness and elasticity, and improve rough skin condition.

A Prospective, single-center, randomized, split-face controlled, single-blind evaluation, superior efficacy clinical trial to evaluate the efficacy and safety of recombinant humanized collagen (type III) solution for injection combined with SkinCeuticals recombinant humanized collagen (RHC) serum, to explore the synergetic effects of injectable integrated skincare in Chinese population.

A total of 54 subjects will be enrolled in this study, and half of the face of each subject will be randomly assigned 1:1 to the test side and the control side.

The subjects will receive one injection of recombinant type III humanized collagen solution and will be followed up for 12 weeks after injection treatment.

Experimental group: SkinCeuticals RHC cream and Regular cream (twice daily) Control group: Regular cream (twice daily)

Participants will be assessed by subjective questionnaire (FACE-Q Satisfaction with skin,Global Aesthetic Improvement Scale, et al) and some medical instruments (VISIA,Ultrascan UC22 et al)

Inclusion Criteria:

• Women between the ages of 30 and 55;
• According to the researchers' judgment, the subjects' facial skin is rough, dry and has obvious fine lines, and the Glogau photoaging rating is II to IV, which can be improved by treatment;
• Subjects voluntarily sign informed consent and agree to complete the follow-up prescribed by the trial.
• Note: All the above items are eligible for inclusion.

Exclusion Criteria:

• The subject has facial scars or skin diseases that may affect the judgment of the treatment effect, is in the stage of allergic attack, or has active infections (such as inflammatory acne, herpes simplex, etc.), and/or unhealed wounds, and is in the stage of progressive skin diseases such as vitiligo, psoriasis, etc.;

• had received or planned to have the following surgery or treatment prior to screening that affected the trial during the study period:

  1. Before screening or during the study period, it is planned to perform comprehensive surgical treatment for facial wrinkles, such as silicone, autologous fat transplantation, facial lift surgery, catch-line lifting, permanent dermal fillers (such as polymethyl methacrylate);
  2. Treatment with semi-permanent dermal fillers (e.g., L-lactic acid, hydroxyapatite, polycaprolactones, etc.) is planned for 18 months before screening or during the study period;
  3. Treatment with biodegradable dermal fillers (such as sodium hyaluronate gel or collagen) planned for 12 months prior to screening or during the study period;
  4. Screening 6 months before or during the study period is planned in the overall Department: Botulinum toxin, plastic therapy, energy equipment other than light conditioning therapy and intense pulse light (such as laser, radio frequency, ultrasound, etc.), skin grinding, chemical exfoliation of medium depth or greater depth or other exfoliative treatment (such as trichloroacetic acid, carbonic acid, 10% or more concentration of fruit acid or 2% or more concentration of salicylic acid, etc.);
  5. Light conditioning therapy, intense pulsed light, shallow exfoliation, or other exfoliative therapy (e.g., hydroxy acid at concentrations below 10% or salicylic acid at concentrations below 2%, etc.) are planned for 3 months prior to screening or during the study period;

• a history of multiple severe or hereditary allergies to any part of the body, who plan to undergo desensitization during the study period, or who are allergic to the ingredients of the drugs or devices used in the experimental treatment (hyaluronic acid, streptococcal protein, lidocaine or other amide anesthetics, etc.);

• the subject has a history of abnormal coagulation function, or has used or plans to use anticoagulation, antiplatelet, or thrombolytic therapy (e.g., warfarin, aspirin, etc.) within 14 days prior to screening;

• pregnancy or breastfeeding, planned pregnancy during the test, or positive pregnancy test results during the screening period;

• The subject has a history of serious diseases of major organs or active autoimmune diseases;

• Those with hypertrophic scars or cicatricial constitution;

• Participants who have participated in other clinical trials within 30 days prior to the screening period;

• The subject is judged by the investigator to have other systemic diseases that are not suitable for participation in the study;

• Subjects who are unable to communicate or do not follow instructions;

• Other conditions that the investigator considers inappropriate to participate in this experiment.

Note: All the above items are "no" to be selected

All data obtained during a clinical trial is owned jointly by the investigator and the clinical trial facility. Under the premise of mutual consultation, the clinical trial institution or the investigator decides to publish the research results.